Cite
HARVARD Citation
Harivenkatesh, N. et al. (n.d.). Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacological research. pp. 138-145. [Online].